Saak Ovsepian
Armenian-Irish neuroscientist
- 3 min read
- 3 chapters
Related on Lably
Through Brain
Education and career
Ovsepian started his education in Heshtia, Republic of Georgia followed by studies of medicine at the Medical College in Tyumen. During this period, he worked as a physician assistant at a local psychiatric asylum. After completing his medical training, he served as a conscript in Germany, working as a military physician. In 1996, Ovsepian enrolled in Omsk State Pedagogical University to study biology, psychology and philosophy. In 1998, he moved to Yerevan, where he graduated from the State University with an MSc in Biology - Human Physiology in 1999. From 2017, he served as a professor, Director of the Experimental Neurobiology Program, Head of the Department of Experimental Neurosciences at the National Institute of Mental Health (NIMH) Klecany, and the 3rd Faculty of Medicine Charles University of Prague. He also worked as a Research Director of Neuroimaging at Dublin City University. Since 2021, he served as a professor in Biosciences and the Lead of Applied Molecular Biology at the University of Greenwich and recently took a voluntary redundancy due to the restructuring and merger of the University into the London & South East University Group (LASE).
Sign in to keep reading
2 more chapters are free with a Lably account.
Research career
Ovsepian has written papers on synaptic biology and pathobiology, translational neuroscience, neurotherapeutics, molecular imaging, and disease biomarkers. In 2014, he proposed the adaptive hypothesis of the origin of the chemical synapse, suggesting that the key molecular scaffolds of synapses evolved independently of neurons. In 2016, he formulated the homeostatic hypothesis of the basal forebrain cholinergic system, which highlights the role of basal-cortical projections in the clearance of amyloid β peptide in the healthy and diseased brain. In 2019, he put forward the brain's dark matter hypothesis, which advocates for a substantial redundancy of neurons in the mammalian brain, maintained in a dormant state. His current research focuses on the molecular and cellular mechanisms underlying normal brain function, neurodegenerative and neuropsychiatric diseases, and biomarkers of brain diseases. He employs advanced imaging and neurophysiology techniques in cell cultures and preclinical models to investigate a wide range of basic and translational biology questions.
Ovsepian's journey in neuroscience began as a research assistant at the Orbeli Institute of Physiology (1998-2000), where he pursued electrophysiology research. He then completed his PhD studies in the laboratory of Synaptic Evolution at the Sechenov Institute of Physiology, with a thesis on the evolution of presynaptic regulatory mechanisms. Following the completion of his doctoral studies, he joined Trinity College Dublin in 2003 as a Research Associate. In 2005, Ovsepian moved to Case Western Reserve University. Later, he joined the Centre for Molecular and Behavioural Neurosciences at the State University of Rutgers, New Jersey. In 2009, he became the Head of Neuroimaging and Drug Screening at the International Centre for Neurotherapeutics, Dublin City University. From 2013 to 2017, Ovsepian served as the Head of Electrophysiology at the German Centre for Neurodegenerative Disease (DZNE) Munich and Chair of Biological Imaging at Munich - Technical University. From 2017 he served as the Director of the Experimental Neurobiology Program at the NIMH Prague. From 2020, he is a professor in Biosciences at the University of Greenwich, London.
Editorships
Ovsepian holds several scientific editorial positions in the field of neuroscience. He serves as an Associate Editor for the Journal of Brain Structure and Function and is a member of the editorial board of the Journal of Evolutionary Biochemistry and Physiology. Ovsepian also serves as a Section Editor of the Brain Sciences journal. He is a reviewer of many journals including Brain, Journal of Neuroscience, Nature Communications, Neuron, Alzheimer's and Dementia, Neurotherapeutics, and others.